

Supplemental Table 1: List of different referring phenotypes related with inherited cardiovascular diseases evaluated through next generation sequencing.

Referring phenotype	Number of studies
Hypertrophic cardiomyopathy	1078
Dilated cardiomyopathy	508
Arrhythmogenic cardiomyopathy	219
	214
Ascending aortic disease/Marfan Syndrome	
Long QT syndrome	188
Left ventricular non-compaction-hypertrabeculation	159
Brugada syndrome	135
Sudden death of unknown cause	131
Idiopathic ventricular fibrillation	52
Catecholaminergic Polymorphic Ventricular Tachycardia	49
Restrictive Cardiomyopathy	45
Noonan Syndrome/Cardiofaciocutaneous Syndrome	30
	19
Cardiac Conduction Disease	
Ehlers-Danlos Syndrome	16
Hereditary hemorrhagic telangiectasia/Primary pulmonary hypertension	16
Short QT syndrome	11
Familial Atrial Fibrillation	7
TOTAL	2877

Supplemental Table 2: List of 213 genes related to inherited cardiovascular diseases and sudden death included in our custom probe library.

Gene name	Codified protein
<i>AARS2</i>	Alanine--tRNA ligase, mitochondrial
<i>ABCC9</i>	ATP-binding cassette, sub-family C (CFTR/MRP), member 9
<i>ACAD9</i>	Acyl-CoA dehydrogenase family member 9, mitochondrial
<i>ACADM</i>	Medium-chain specific acyl-CoA dehydrogenase, mitochondrial
<i>ACADVL</i>	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial
<i>ACTA1</i>	Actin, alfa 1, skeletal muscle
<i>ACTA2</i>	Actin, aortic smooth muscle
<i>ACTC1</i>	Actin, alpha cardiac muscle 1
<i>ACTN2</i>	Alpha-actinin-2
<i>ACVRL1</i>	Serine/threonine-protein kinase receptor R3
<i>ADAMTSL4</i>	ADAMTS-like protein 4
<i>AGK</i>	Acylglycerol kinase, mitochondrial
<i>AGL</i>	Glycogen debranching enzyme
<i>AGPAT2</i>	1-acyl-sn-glycerol-3-phosphate acyltransferase beta
<i>AKAP9</i>	A-kinase anchor protein 9
<i>ALMS1</i>	Alstrom syndrome protein 1
<i>ANK2</i>	Ankyrin 2
<i>ANK3</i>	Ankyrin-3
<i>ANKRD1</i>	Ankyrin repeat domain-containing protein 1
<i>APOA5</i>	Apolipoprotein A-V
<i>APOB</i>	Apolipoprotein B-100
<i>APOC3</i>	Apolipoprotein C-III
<i>ATPAF2</i>	ATP synthase mitochondrial F1 complex assembly factor 2
<i>BAG3</i>	BAG family molecular chaperone regulator 3
<i>BMPR1B</i>	Bone morphogenetic protein receptor type-1B
<i>BMPR2</i>	Bone morphogenetic protein receptor type II
<i>BRAF</i>	Serine/threonine-protein kinase B-raf
<i>BSCL2</i>	Seipin
<i>CACNA1C</i>	Voltage-dependent L-type calcium channel subunit alpha-1C
<i>CACNA1D</i>	Voltage-dependent L-type calcium channel subunit alpha-1D
<i>CACNA2D1</i>	Voltage-dependent calcium channel subunit alpha-2/delta-1
<i>CACNB2</i>	Voltage-dependent L-type calcium channel subunit beta-2
<i>CALM1</i>	Calmodulin
<i>CALM2</i>	Calmodulin
<i>CALR3</i>	Calreticulin 3
<i>CAPN3</i>	Calpain-3
<i>CASQ2</i>	Calsequestrin-2
<i>CAVI</i>	Caveolin-1
<i>CAV3</i>	Caveolin-3
<i>CBL</i>	E3 ubiquitin-protein ligase CBL
<i>CBS</i>	Cystathionine beta-synthase

<i>CETP</i>	Cholesteryl ester transfer protein
<i>COL1A1</i>	Collagen alpha-1(I) chain
<i>COL1A2</i>	Collagen alpha-2(I) chain
<i>COL3A1</i>	Collagen alpha-1(III) chain
<i>COL5A1</i>	Collagen alpha-1(V) chain
<i>COL5A2</i>	Collagen alpha-2(V) chain
<i>COQ2</i>	4-hydroxybenzoate polyprenyltransferase, mitochondrial
<i>COX15</i>	Cytochrome c oxidase assembly protein COX15 homolog
<i>COX6B1</i>	Cytochrome c oxidase subunit 6B1
<i>CRELD1</i>	Cysteine-rich with EGF-like domain protein 1
<i>CRYAB</i>	Alpha-crystallin B chain
<i>CSRP3</i>	Cysteine and glycine-rich protein 3
<i>CTF1</i>	Cardiotrophin 1
<i>CTNNA3</i>	Catenin alpha-3
<i>DES</i>	Desmin
<i>DLD</i>	Dihydrolipoyl dehydrogenase, mitochondrial
<i>DMD</i>	Dystrophin
<i>DNAJC19</i>	Mitochondrial import inner membrane translocase subunit TIM14
<i>DOLK</i>	Dolichol kinase
<i>DSC2</i>	Desmocollin 2
<i>DSG2</i>	Desmoglein 2
<i>DSP</i>	Desmoplakin
<i>DTNA</i>	Dystrobrevin alpha
<i>ELN</i>	Elastin
<i>EMD</i>	Emerin
<i>ENG</i>	Endoglin
<i>EYA4</i>	Eyes absent homolog 4
<i>FAH</i>	Fumarylacetoacetate
<i>FBN1</i>	Fibrillin 1
<i>FBN2</i>	Fibrillin 2
<i>FHL1</i>	Four and a half LIM domains protein 1
<i>FHL2</i>	Four and a half LIM domains 2
<i>FHOD3</i>	FH1/FH2 domain-containing protein 3
<i>FKRP</i>	Fukutin-related protein
<i>FKTN</i>	Fukutin
<i>FLNA</i>	Filamin-A
<i>FLNC</i>	Filamin-C
<i>FOXD4</i>	Forkhead box protein D4
<i>GAA</i>	Lysosomal alpha-glucosidase
<i>GATA4</i>	Transcription factor GATA-4
<i>GATA6</i>	Transcription factor GATA-6
<i>GATAD1</i>	GATA zinc finger domain-containing protein 1
<i>GDF2</i>	Growth/differentiation factor 2
<i>GFM1</i>	Elongation factor G, mitochondrial
<i>GJA1</i>	Gap junction alpha-1 protein

<i>GJA5</i>	Gap junction alpha-5 protein
<i>GLA</i>	Alpha-galactosidase A
<i>GLB1</i>	Beta-galactosidase
<i>GNPTAB</i>	N-acetylglucosamine-1-phosphotransferase subunits alpha/beta
<i>GPD1L</i>	Glycerol-3-phosphate dehydrogenase 1-like protein
<i>GUSB</i>	Beta-glucuronidase
<i>HCN4</i>	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
<i>HFE</i>	Hereditary hemochromatosis protein
<i>HRAS</i>	GTPase HRas
<i>JAG1</i>	Jagged-1
<i>JPH2</i>	Junctophilin 2
<i>JUP</i>	Junction plakoglobin
<i>KCNA5</i>	Potassium voltage-gated channel subfamily A member 5
<i>KCND3</i>	Potassium voltage-gated channel subfamily D member 3
<i>KCNE1</i>	Potassium voltage-gated channel subfamily E member 1
<i>KCNE1L</i>	Potassium voltage-gated channel subfamily E member 1-like protein
<i>KCNE2</i>	Potassium voltage-gated channel subfamily E member 2
<i>KCNE3</i>	Potassium voltage-gated channel subfamily E member 3
<i>KCNH2</i>	Potassium voltage-gated channel subfamily H member 2
<i>KCNJ2</i>	Inward rectifier potassium channel 2
<i>KCNJ5</i>	G protein-activated inward rectifier potassium channel 4
<i>KCNJ8</i>	ATP-sensitive inward rectifier potassium channel 8
<i>KCNK3</i>	Potassium channel subfamily K member 3
<i>KCNQ1</i>	Potassium voltage-gated channel subfamily KQT member 1
<i>KLF10</i>	Krueppel-like factor 10
<i>KRAS</i>	GTPase KRas
<i>LAMA2</i>	Laminin subunit alpha-2
<i>LAMA4</i>	Laminin subunit alpha-4
<i>LAMP2</i>	Lysosome-associated membrane glycoprotein 2
<i>LDB3</i>	LIM domain-binding protein 3
<i>LDLR</i>	Low density lipoprotein receptor
<i>LIAS</i>	Lipoyl synthase, mitochondrial
<i>LMNA</i>	Prelamin-A/C
<i>LRP6</i>	Low-density lipoprotein receptor-related protein 6
<i>MAP2K1</i>	Dual specificity mitogen-activated protein kinase kinase 1
<i>MAP2K2</i>	Dual specificity mitogen-activated protein kinase kinase 2
<i>MIB1</i>	E3 ubiquitin-protein ligase MIB1
<i>MLYCD</i>	Malonyl-CoA decarboxylase, mitochondrial
<i>MRPL3</i>	39S ribosomal protein L3, mitochondrial
<i>MRPS22</i>	28S ribosomal protein S22, mitochondrial
<i>MTO1</i>	Protein MTO1 homolog, mitochondrial
<i>MURC</i>	Muscle-related coiled-coil protein
<i>MYBPC3</i>	Myosin-binding protein C, cardiac-type
<i>MYH11</i>	Myosin-11
<i>MYH6</i>	Myosin-6

<i>MYH7</i>	Myosin-7
<i>MYL2</i>	Myosin regulatory light chain 2, ventricular/cardiac muscle isoform
<i>MYL3</i>	Myosin light chain 3
<i>MYLK</i>	Myosin light chain kinase, smooth muscle
<i>MYLK2</i>	Myosin light chain kinase 2, skeletal/cardiac muscle
<i>MYOT</i>	Myotilin
<i>MYOZ2</i>	Myozenin 2
<i>MYPN</i>	Myopalladin
<i>NEBL</i>	Nebulette
<i>NEXN</i>	Nexilin
<i>NKX2-5</i>	Homeobox protein Nkx-2.5
<i>NOTCH1</i>	Neurogenic locus notch homolog protein 1
<i>NOTCH3</i>	Neurogenic locus notch homolog protein 3
<i>NPPA</i>	Atrial natriuretic factor
<i>NRAS</i>	GTPase NRas
<i>OBSL1</i>	Obscurin-like protein 1
<i>PCSK9</i>	Proprotein convertase subtilisin/kexin type 9
<i>PDHA1</i>	Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial
<i>PDLIM3</i>	PDZ and LIM domain protein 3
<i>PHKA1</i>	Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform
<i>PITX2</i>	Pituitary homeobox 2
<i>PKP2</i>	Plakophilin 2
<i>PLN</i>	Cardiac phospholamban
<i>PLOD1</i>	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1
<i>PMM2</i>	Phosphomannomutase 2
<i>PRDM16</i>	PR domain zinc finger protein 16
<i>PRKAG2</i>	5'-AMP-activated protein kinase subunit gamma-2
<i>PRKG1</i>	cGMP-dependent protein kinase 1
<i>PSEN1</i>	Presenilin-1
<i>PSEN2</i>	Presenilin 2
<i>PTPN11</i>	Tyrosine-protein phosphatase non-receptor type 11
<i>RAF1</i>	RAF proto-oncogene serine/threonine-protein kinase
<i>RANGRF</i>	Ran guanine nucleotide release factor
<i>RBM20</i>	Probable RNA-binding protein 20
<i>RYR2</i>	Ryanodine receptor 2
<i>SCN10A</i>	Sodium channel protein type 10 subunit alpha
<i>SCN1B</i>	Sodium channel subunit beta-1
<i>SCN2B</i>	Sodium channel subunit beta-2
<i>SCN3B</i>	Sodium channel subunit beta-3
<i>SCN4B</i>	Sodium channel subunit beta-4
<i>SCN5A</i>	Sodium channel protein type 5 subunit alpha
<i>SGCA</i>	Alpha-sarcoglycan
<i>SGCB</i>	Beta-sarcoglycan
<i>SGCD</i>	Delta-sarcoglycan
<i>SHOC2</i>	Leucine-rich repeat protein SHOC-2

<i>SKI</i>	Ski oncogene
<i>SLC22A5</i>	Solute carrier family 22 member 5
<i>SLC25A4</i>	ADP/ATP translocase 1
<i>SLC2A10</i>	Solute carrier family 2, facilitated glucose transporter member 10
<i>SLMAP</i>	Sarcolemmal membrane-associated protein
<i>SMAD1</i>	Mothers against decapentaplegic homolog 1
<i>SMAD3</i>	Mothers against decapentaplegic homolog 3
<i>SMAD4</i>	Mothers against decapentaplegic homolog 4
<i>SMAD9</i>	Mothers against decapentaplegic homolog 9
<i>SNTA1</i>	Alpha-1-syntrophin
<i>SOS1</i>	Son of sevenless homolog 1
<i>SPRED1</i>	Sprouty-related, EVH1 domain-containing protein 1
<i>SURF1</i>	Surfeit locus protein 1
<i>TAZ</i>	Tafazzin
<i>TBX1</i>	T-box transcription factor TBX1
<i>TBX20</i>	T-box transcription factor TBX20
<i>TBX5</i>	T-box transcription factor TBX5
<i>TCAP</i>	Telethonin
<i>TGFB2</i>	Transforming growth factor beta-2
<i>TGFB3</i>	Transforming growth factor, beta 3
<i>TGFBR1</i>	TGF-beta receptor type-1
<i>TGFBR2</i>	TGF-beta receptor type-2
<i>TMEM43</i>	Transmembrane protein 43
<i>TMEM70</i>	Transmembrane protein 70, mitochondrial
<i>TMPO</i>	Thymopoietin
<i>TNNC1</i>	Troponin C, slow skeletal and cardiac muscles
<i>TNNI3</i>	Troponin I, cardiac muscle
<i>TNNT2</i>	Troponin T, cardiac muscle
<i>TPM1</i>	Tropomyosin alpha-1 chain
<i>TRDN</i>	Triadin
<i>TRIM63</i>	E3 ubiquitin-protein ligase TRIM63
<i>TRPM4</i>	Transient receptor potential cation channel subfamily M member 4
<i>TSFM</i>	Elongation factor Ts, mitochondria
<i>TTN</i>	Titin
<i>TTR</i>	Transthyretin
<i>TXNRD2</i>	Thioredoxin reductase 2, mitochondrial
<i>VCL</i>	Vinculin

Supplemental Table 3. List of mutations identified in the *FLNC* gene with their predicted functional effect on the protein and their frequency in different public databases.

Exon/ Intron	Chr DNA level name	c.DNA	Protein	Predicted functional effect	1KG	EVS	ExAC	Previously reported
Ex1	Chr7:128470932delC	c.241delC	p.Arg81Alafs*15	Introduces a premature stop codon at amino acid 95, after 14 novel residues. Truncation in the CH1 domain at the ABD.	-	-	-	-
Ex1	Chr7:128470940C>G	c.249C>G	p.Tyr83*	Truncation in the CH1 domain at the ABD.	-	-	-	-
Ex2	Chr7:128475608_128475626delTGGTGG ACAACTGCGCCCC	c.581_599delTGGTGG GACAAC TGCGCCCC C	p.Leu194Profs*52	Truncation in the CH2 domain at the ABD.	-	-	-	-
Ex3-6	Chr7:128476498_128478081delinsTGCCC CGGGAGGGGTGCCTCAGTCTCCCTG TCCCTCTG	c.602- 716_1010delinsTGC CCCAGGGAGGGGT GCCTCAGTCTCCC TGTCCCTCTG	p.Gly201Valfs*36	Complete deletion of exons 3, 4, 5, and part of 6. Truncation in the CH2 domain. Eliminates the splicing acceptor of exon 3. Possible skipping of exon 3 with a loss of amino acids 201-233 (CH2 domain at the ABD), frame shift at this point, addition of 3 new amino acids, and stop codon at position (c.711). Implies the loss of the last 2524 amino acids.	-	-	-	-
Ex11	Chr7:128480925C>T	c.1714C>T	p.Gln572*	Truncation in the Ig-repeat 4.	-	-	-	-
Ex14	Chr7:128482371delT	c.2208delT	p.Lys737Serfs*11	Truncation in the Ig-repeat 5.	-	-	-	-
Ex19	Chr7:128483926delC	c.2888delC	p.Pro963Argfs*26	Truncation in the Ig-repeat 8.	-	-	1/120492	-
Ex21	Chr7:128484921_128484922dupGCGAGT ACACCATCAACATCCTG	c.3402_3403dupGCG AGTACACCATCAA CATCCTG	p.Phe1135Alafs*62	Truncation in the Ig-repeat 10.	-	-	-	-
Int21	Chr7:128486043G>A	c.3791-1G>A	-	Eliminates the splicing acceptor of exon 22. Possible skipping of exon 22 with a loss of amino acids 1265-1322 (Ig-repeat 11).	-	-	-	-
Int21	Chr7:128486043G>C	c.3791-1G>C (2)	-	Eliminates the splicing acceptor of exon 22. Possible skipping of exon 22 with a loss of amino acids 1265-1322 (Ig-repeat 11).	-	-	1/118498	Two cases with dilated cardiomyopathy (1,2)
Int22	Chr7:128486353A>T	c.3965-2A>T (2)	-	Eliminates the splicing acceptor of exon 23. Possible skipping of exon 23 with a loss of amino acids 1322-1376 (Ig-repeat 11-12), frame shift at this point, addition of 8 new amino acids, and stop codon at position 1330 (c.4154). Implies the loss of the last 1403 amino acids.	-	-	-	-
Ex23	Chr7:128486496_128486497dupA	c.4106_4107dupA	p.Asn1369Lysfs*36	Truncation in the Ig-repeat 12.	-	-	-	-
Int23	Chr7:128486518delG	c.4127+1delG (2)	-	Abolishes the splicing donor of exon 23. Two alternatives: 1) A possible loss of amino acid 1376 (Ig-repeat 12), frame shift at this point, addition of 6 new amino acids, and stop codon at position (c.4127+18). Implies the loss of the last 1350 amino acids.	-	-	-	-

				2) Possible skipping of exon 23 (Ig-repeat 12), frame shift at this point, addition of 9 new amino acids, and stop codon at position 1386 (c.4154). Implies the loss of the last 1401 amino acids.				
Int26	Chr7:128488123G>T	c.4580+1G>T	-	Eliminates the splicing donor of exon 26. Possible skipping of exon 26 with a loss of amino acids 1486-1527 (Ig-repeat 13), frame shift at this point, addition of 80 new amino acids, and stop codon at position 1566 (c.4817). Implies the loss of the last 1239 amino acids.	-	-	-	-
Int28	Chr7:128489037delG	c.4927+1delG	-	Abolishes the splicing donor of exon 28. Two alternatives: 1) A possible loss of amino acid 1643 (Ig-repeat 15), frame shift at this point, addition of 53 new amino acids, and stop codon at position (c.4928-38). Implies the loss of the last 1083 amino acids. 2) Possible skipping of exon 28, (Ig-repeat 15), frame shift at this point, addition of 22 new amino acids, and stop codon at position 1665 (c.4994). Implies the loss of the last 1145 amino acids.	-	-	-	-
Ex32	Chr7:128490537G>T	c.5398G>T (2)	p.Gly1800*	Truncation in the Ig-repeat 16.	-	-	-	-
Int33	Chr7:128490998G>C	c.5539+1G>C	-	Abolishes the splicing donor of exon 33. Possible skipping of exon 33 with a loss of amino acids 1800-1846 (Ig-repeat 16).	-	-	-	-
Ex37	Chr7:128493085G>A	c.6208G>A	p.Gly2070Ser	The splicing is likely to be altered (as predicted by 3 software tools) but the consequences are not predictable.	-	-	-	-
Ex38	Chr7:128493545delT	c.6231delT	p.Ser2077Argfs*50	Truncation in the Ig-repeat 19.	-	-	-	-
Ex38	Chr7:128493554_128493573delCCCAAG CAAGGTGGACATCA	c.6240_6259delCCC AAGCAAGGTGGA CATCA	p.Pro2081Leufs*2	Truncation in the Ig-repeat 19.				-
Ex41	Chr7:128494715C>T	c.6976C>T (2)	p.Arg2326*	Truncation in the Ig-repeat 21.	-	-	1/111082	-
Int43	Chr7:128495369G>A	c.7251+1G>A	-	Abolishes the splicing donor of exon 43. Possible skipping of exon 43 (Ig-repeat 21 and 22), frame shift at this point, addition of 23 new amino acids, and stop codon at position 2440 (c.7320). Implies the loss of the last 346 amino acids.	-	-	-	Two families with dilated cardiomyopathy (3)
Ex48	Chr7:128498506delG	c.8107delG	p.Asp2703Thrfs*69	Replacement of 23 amino acids at the C-terminal tail (dimerization domain) and extension of 45 amino acids.	-	-	-	-

ABD= actin binding domain. Ig-repeat= immunoglobulin-like repeat. CH1= calponin homology domain 1. CH2= calponin homology domain 2. (2)= mutations identified in two unrelated families. Reference sequence for names at chromosomal DNA level: NC_000007.13; cDNA level: NM_001458.4; protein level: NP_001449.3. 1KG= 1000 Genomes Project. EVS= Exome Variant Server. ExAC= Exome Aggregation Consortium. Frequency is expressed N° of alternative alleles/Total N° of alleles.

Supplemental Table 4: Detailed clinical information on *FLNC* mutation carriers.

Family	Ind	Mutation	Age Dx	Age LFU	Sex	FH SD	Clinical press	SM	Pheno	LV DD	LV EF	MW T	RV affect	CK	Rhyth m	CCD	Low Volt	Neg Tw	Ter QRS> 55	Vent arrhyt	EPS	LGE on MRI	LV NC	Pathology	Events	Age at event	ICD	Comments
25767	III:1	Ser2077Argfs*50	48	52	M	+	D	-	DCM	83	27	norm al	+	N	S	LBBB	-	n/a	n/a	n/a	n/a	n/a	-	No fibrosis; myocyte degeneration; RV lymphocytic infiltration	HTx	52		
25767	III:2	Ser2077Argfs*50	59	59	M		P, AF	-	DCM	67	35	10	-	n/a	S	-	-	V4-V6	+	n/a	n/a	n/a	-	n/a	n			
25767	IV:1	Ser2077Argfs*50		33	F	n		-	Healthy	42	65	9	-	n/a	S	-	-	-	n/a	n/a	n/a	n/a	-	n/a	n			
25767	IV:3	Ser2077Argfs*50		30	F	n		-	Healthy	44	65	6	-	n/a	S	-	-	-	n/a	n/a	n/a	n/a	-	n/a	n			
26958	II:1	Tyr83*		17	17	M	+	SD	-	LDACM	n/a	n/a	norm al	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	LV subepicardial fibrosis	SD	17	SD after a soccer match.	
26958	I:1	Tyr83*		49	49	M		n	-	Affected?	53	60	12	+	n/a	S	-	-	-	-	n/a	n	-	n/a	n		Mild dyskinetic zone/saculation on anterior RV wall on cardiac-MRI.	
27103	III:1	c.3791-1G>C	45	52	F	+	n	-	DCM	58	35	8	-	n/a	S	-	-	-	-	FVE, NSVT, SVT	n/a	n/a	-	n/a	aICDs	52	2°	SVT on effort on routine effort test. ICD discharge: VT on exercise. Positive delay potencials on SAECG.
27103	IV:1	c.3791-1G>C		26	M		n	-	Healthy	normal	normal	normal	-	n/a	S	-	-	-	-	n/a	n	-	n/a	n		Normal SAECG.		

27348	II:3	Asn1369Lysfs*36	20	60	M	+	SVT	-	DCM	82	32	13	+	N	AF	-	+	V4-V6	+	SVT	n/a	n/a	-	LV endomyocardial fibroelastosis	aICDs; HTx	21; 60	2°	SVT requiring shocks (20,21,34 yo). Urgent HTx; severe RV systolic dysfunction.
27348	III:2	Asn1369Lysfs*36	34	38	F		FVE	-	Affected?	45	64	10	-	n/a	S	-	-	-	-	FVE	n/a	n/a	-	n/a	n			
29544	III:2	Pro963Argfs*26	0.25	1	F	-	D	-	DCM	40	22	normal	-	N	S	-	-	-	-	n/a	n/a	n/a	-	LV myocardial fibrosis and endomyocardial fibroelastosis	HTx	1		
29544	II:1	Pro963Argfs*26	40	40	F		n	-	Affected?	dilated	47	10	-	n/a	S	-	+	-	-	-	n/a	n	+	n/a	n			Mild LV dilatation and systolic dysfunction.
29544	III:1	Pro963Argfs*26	9	9	F		n	-	Affected?	46	69	6	-	n/a	S	-	-	-	-	n/a	n/a	n/a	+	n/a	n			Bicuspid aortic valve with mild insufficiency.
29876	III:3	c.4127+1delG	19	25	M	+	S, P	-	LDACM	61	54	11	-	N	S	-	-	-	-	FVE, SVT	n/a	LV (subepicardial)	+	LV fibrosis	aICDs; SD	25	2°	SVT playing football, ICD implant, death on electric storm. Palmoplantar keratosis.
29876	II:5	c.4127+1delG	43	57	M		S, P	-	DCM	60	50	12	-	N	S	-	-	-	-	SVT	SVT	n/a	-	n/a	aICDs	51	2°	Syncpe playing football secondary to SVT. Several ICD interventions due to SVT. Palmoplantar keratosis.
29876	II:3	c.4127+1delG	60	60	F		n	-	LDACM	51	67	12	-	n/a	S	-	-	-	-	FVE	n/a	LV (intramyocardial)	-	n/a	n			

29876	II:4	c.4127+1delG	35	59	M		D, S	-	DCM	64	43	11	-	n/a	AF	LAFB	-	-	-	FVE, NSVT	n/a	n	-	n/a	n		Palmoplantar keratosis.	
29876	II:7	c.4127+1delG	54	56	M		n	-	LDACM	normal	mil d	norm al	-	n/a	S	-	-	n/a	n/a	FVE, NSVT	n/a	LV (subepicar dial)	-	n/a	n		Palmoplantar keratosis.	
29876	III:5	c.4127+1delG	21	21	M		n	-	LDACM	51	52	10	-	n/a	S	-	-	-	-	n/a	LV (intramyoc ardial)	-	n/a	n				
31035	IV:1	c.7251+1G>A	26	33	F	+	NSVT	-	DCM	66	23	6	-	N	S	-	+	V3- V6	+	NSVT	-	n/a	-	n/a	n	1°		
31035	III:2	c.7251+1G>A	38	61	F		n	-	DCM	64	33	10	-	n/a	S	-	+	V1- V5	+	n/a	n/a	n/a	-	n/a	n	1°		
31035	IV:4	c.7251+1G>A		39	F		n	-	Healthy	52	68	6	-	n/a	S	-	-	-	-	n/a	n	-	n/a	n				
31035	III:5	c.7251+1G>A	58	63	F		n	-	DCM	66	35	8	-	n/a	S	-	-	V1- V6	+	FVE	n/a	n/a	-	n/a	n	1°		
31035	IV:6	c.7251+1G>A	39	39	F		n	-	Affected?	46	54	8	-	n/a	S	-	-	-	-	n/a	n/a	-	n/a	n				
31035	IV:7	c.7251+1G>A	40	40	F		SD	n/a	LDACM	n/a	n/a	norm al	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	LV concentric subepicardial fibrosis	SD	40			
31277	II:2	c.4927+1 delG	29	55	F	-	D	+	RCM	32	66	14	-	Mil d	AF	1°AVB	-	V5- V6	-	n/a	n/a	n/a	-	RV fibrosis (endomyocar dial biopsy)	HTx	45		
32406	III:2	Gln572*	20	22	M	+	P	-	LDACM	68	37	norm al	+	n/a	S	-	+	V5- V6	-	FVE	n/a	LV (subepicar dial and intramyoca rdial)	-	LV concentric subepicardial fibrosis	SD	22	1° (ind)	SD playing football (waiting ICD implant).
33319	II:1	c.4127+1delG	53	63	M	-	D	-	DCM	dilat ed	15	n/a	+	N	AF	-	n/a	n/a	n/a	n/a	n/a	LV (transmura l)	n/a	n/a	n			
33319	III:2	c.4127+1delG	30	31	M		CP	-	LDACM	nor mal	57	norm al	-	mil d	S	-	-	-	-	n/a	n/a	LV (intramyoc ardial)	n/a	n/a	n			
33319	III:1	c.4127+1delG		32	F		n	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n					
33541	II:3	c.5539+1G>C	60	68	M	+	D, CP, FVE	-	DCM	60	40	11	-	N	AF	LAFB	-	Inf, V4- V6	-	FVE, NSVT	n/a	LV (subepicar dial and intramyoca rdial)	-	n/a	n	1°		
33541	II:5	c.5539+1G>C	55	63	M		SD	-	DCM	dilat ed	45	11	-	N	S	-	+	-	-	SVT	n/a	LV (subepicar dial and intramyoca rdial)	-	n/a	SD; aICDs	55	2°	Multiple appropriate ICD shocks due to SVT/VF.

33541	II:6	c.5539+1G>C	59	60	F		S, D, P	-	Affected?	50	55	9	-	N	S	-	-	-	-	FVE	n/a	LV (intramyocardial)	-	n/a	n			
33541	III:1	c.5539+1G>C		39	F	n		-	Healthy	38	60	8	-	N	S	-	-	-	-	n/a	n	-	n/a	n				
33675	II:1	Gly1800*	55	59	M	-	P	-	LDACM	59	45	9	+	X2	S	-	-	V3-V6	-	FVE, NSVT	n/a	LV (subepicardial)	+	n/a	n		1°	Positive delay potencials on SAECG.
33675	II:2	Gly1800*	60	63	M	n		-	Affected?	37	67	14	-	N	S	-	-	-	-	n/a	n/a	n	+	n/a	n			HTN.
36107	II:9	Arg2326*	54	59	F	+	D	-	DCM	dilated	20	norm al	+	N	S	LBBB	+	n/a	n/a	FVE, NSVT	n/a	LV (subepicardial)	-	n/a	HTx	57		Emergent HTx.
36107	II:4	Arg2326* (o)	52	58	F		D	n/a	DCM	dilated	25	norm al	-	n/a	S	-	+	V1-V4	-	NSVT	n/a	LV basal septum	-	n/a	SD	58		Listed for HTx prior to SD.
36107	II:6	Arg2326*	57	59	F		S, P	-	Affected?	54	56	8	-	N	S	-	+	Inf, V1-V6	+	FVE	-	n	-	n/a	n			
36107	III:7	Arg2326*		33	M	n		-	Healthy	54	60	8	-	N	S	-	-	-	-	n/a	n/a	n	-	n/a	n			
36107	III:2	Arg2326*	33	34	M		S, P	-	DCM	60	46	11	+	N	S	-	-	-	+	FVE	n/a	LV (subepicardial)	-	n/a	aICDs	33	1°	Multiple SVT treated by the ICD.
36107	III:3	Arg2326*	33	38	F		D	-	DCM	57	35	12	-	N	S	-	-	-	-	FVE, NSVT	n/a	LV (intramyocardial)	-	n/a	n		1° (ind)	Declined ICD.
36203	III:1	Gly1800*	38	43	M	+	P	-	LDACM	dilated	50	10	-	n/a	S	-	-	Inf, V6	-	FVE, NSVT	n/a	LV (subepicardial and intramyocardial)	-	n/a	n		1°	Abnormal Q wave DIII and aVF.
36203	III:3	Gly1800*	28	38	M		P	-	LDACM	54	51	11	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	LV fibrosis posterior wall	SD	38		
36203	II:1	Gly1800*	71	74	M		S, CP	-	LDACM	46	41	11	-	N	S	-	-	Inf	n/a	FVE	n/a	LV (subepicardial and intramyocardial)	-	n/a	n		1°	Abnormal Q wave in DIII.
36203	IV:2	Gly1800*		6	F		n	-	Healthy	28	70	6	-	n/a	S	-	-	V1-V3 (6 years)	-	n/a	n/a	n/a	-	n/a	n			
37286	IV:2	Asp2703Thrfs*69	24	24	F	+	Stroke	-	DCM	63	26	7	-	N	S	-	+	Inf, V1-V3	-	NSVT	n/a	n	+	n/a	Stroke	24		

37286	III:1	Asp2703Thrfs*69	43	59	M	S	-	DCM	70	40	7	n/a	N	AF	-	-	Inf	-	SVT	-	n/a	n/a	n/a	aICDs	51	1°	2 ICD shocks on VF.	
37296	II:2	Arg2326*	34	43	F	+ D	-	DCM	70	35	11	-	N	PM	-	+	Inf, V3-V6	n/a	FVE, NSVT	VF	n/a	-	n/a	n/a	aICDs	38	1°	Heart failure during pregnancy. Diastolic restrictive filling pattern. VF induction on EPS. 3 appropriate ICD shocks due to SVT (38, 39, 40 yo) and 1 due to VF (38 yo).
37302	I:1	Gly2070Ser	50	68	M	+ D	-	DCM	78	21	normal	+	n/a	S	1°AVB	-	n/a	n/a	NSVT	n/a	n/a	-	n/a	SD	68		Heart failure at presentation; sudden death in worsening heart failure	
37302	II:1	Gly2070Ser	24	34	M	n/a	n/a	Affected?	n/a	norma	normal	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n			Perimyocarditis .	
37302	II:2	Gly2070Ser	24	32	M	n/a	n/a	Affected?	n/a	norma	normal	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n			Perimyocarditis.	
41721	II:2	c.3791-1G>A	42	61	F	+ P	-	DCM	56	43	9	-	N	S	LAFB+ RBBB	-	-	-	-	n/a	n	-	n/a	n				
41721	II:4	c.3791-1G>A	44	52	M	n	-	DCM	65	45	10	-	N	S	-	-	-	-	NSVT	-	n	-	n/a	n			NSVT during effort test.	
41721	II:7	c.3791-1G>A (o)			F	n/a	n/a	DCM	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	SD	?				
41721	III:1	c.3791-1G>A	20	34	M	n	-	DCM	64	49	10	-	N	S	-	-	-	-	FVE, NSVT	n/a	n/a	-	n/a	n			Positive delay potencials on SAECG.	
41721	III:5	c.3791-1G>A	27	33	M	n	-	DCM	57	34	11	-	N	S	-	+	V3-V6	-	FVE, NSVT	n/a	n	-	n/a	SD	33			
47263	III:2	Phe1135Alafs*62	53	55	F	+ n	-	DCM	56	20	12	-	N	S	-	-	-	-	FVE, NSVT	n/a	n/a	-	n/a	n		1°	CRT-D	
47253	IV:3	Phe1135Alafs*62		24	M	n	-	Healthy	54	68	8	-	n/a	S	-	-	-	-	n/a	n/a	-	n/a	n					
47263	IV:1	Phe1135Alafs*62		30	F	n	-	Healthy	50	73	9	-	n/a	S	-	-	-	-	n/a	n/a	-	n/a	n					

47263	IV:2	Phe1135Alafs*62	28	29	M	n	-	Affected?	60	53	11	-	n/a	S	-	-	-	+	n/a	n/a	n	-	n/a	n		Abnormal Q wave DIII.		
48028	III:1	Lys737Serfs*11	58	62	F	+	D, FVE, NSVT	-	DCM	49	35	9	-	N	S	-	-	-	+	FVE, NSVT	n/a	LV (intramyocardial)	-	n/a	n			
48028	III:2	Lys737Serfs*11	44	60	F		D, P	-	DCM	57	40	8	+	n/a	S	-	-	-	+	FVE, NSVT	n/a	n/a	-	RV fibrosis (endomyocardial biopsy)	n			
48028	IV:1	Lys737Serfs*11		31	F	n		-	Healthy	46	60	7	-	n/a	S	-	-	-	-	n/a	n/a	n/a	-	n/a	n			
48102	II:1	c.3791-1G>C	44	50	M	+	S	-	DCM?	52	50	11	-	n/a	S	-	+	Inf	-	NSVT	n/a	n/a	-	n/a	SD	44	2°	NSVT on effort test and posterior akinesis on echo before an aborted SD.
48102	II:2	c.3791-1G>C	48	48	F		FVE	-	Affected?	normal	57	normal	+	n/a	S	-	+	-	-	FVE	NSVT	n	-	n/a	n		Mild regional RV anterior wall hypokinesis with normal RV size.	
48102	I:1	c.3791-1G>C		78	M	n		-	Unknown	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n		CABG. Known to have "arrhythmias" (reported as extrasystoles) after surgery, treated with sotalol.		
48924	IV:4	p.Leu194Profs*52	21	21	M	+	P	-	DCM	60	38	8	-	N	S	-	-	Inf, V4-V6	-	FVE, NSVT	n/a	n	-	n/a	n		1°	
48924	III:2	p.Leu194Profs*52	60	60	M		SD	-	DCM	n/a	n/a	n/a	+	n/a	S	-	+	-	-	n/a	n/a	n/a	-	Bi-ventricular dilatation (fibrosis not evaluated)	SD	60		
48924	III:1	p.Leu194Profs*52	51	51	F	n		-	Affected?	51	49	10	-	N	S	-	-	-	-	n/a	n	-	n/a	n				
48924	IV:1	p.Leu194Profs*52		18	M	n		-	Healthy	49	60	10	-	n/a	S	-	-	-	-	n/a	n	-	n/a	n		Myocarditis aged 13.		
49537	I:1	c.3965-2A>T	55	66	M	-	D, CP, SVT	-	DCM	81	15	8	+	N	S	LBBB	-	n/a	n/a	FVE, NSVT, SVT	n/a	n/a	-	n/a	aICDs	62	2°	

49537	II:1	c.3965-2A>T	36	41	M		P, SVT	-	DCM	52	42	11	-	n/a	S	-	-	-	-	SVT	n/a	n/a	-	n/a	n		2°		
49537	III:3	c.3965-2A>T	34	38	M		P	-	DCM	61	45	10	-	N	S	-	-	-	-	FVE	n/a	LV (intramyocardial)	+	n/a	n		1°		
48888	IV:1	Pro2081Leufs*2	33	34	M	+	n	-	DCM	66	40	11	-	n/a	S	-	-	-	-	FVE, NSVT	n/a	LV (subepicardial and intramyocardial)	-	n/a	n		1°		
48888	IV:2	Pro2081Leufs*2	36	36	M		n	-	DCM	58	56	9	-	n/a	S	-	-	-	-	FVE	n/a	LV (subepicardial and intramyocardial)	-	n/a	n		Positive delay potencials on SAECG.		
48956		c.4580+1G>T	53	75	M	-	S, CP, SVT	-	LDACM	49	47	14	-	N	S	-	+	V4-V6	+	FVE, NSVT, SVT	n/a	LV (transmural)	-	n/a	n		2°		
48868		Gly201Valfs*36	47	48	M	+	D, CP, NSVT	-	DCM	71	36	11	+	N	S	LBBB	n/a	n/a	n/a	FVE, NSVT	n/a	n	-	n/a	Stroke	47		ECG not informative due to LBBB.	
49818		c.3965-2A>T	62	64	M	+	D	-	DCM	54	18	13	+	N	S	-	+	Inf	+	FVE, NSVT, SVT	n/a	n/a	-	n/a	n		LVEF recovered to 40% after medical treatment.		
51118	II:1	Arg81Alafs*15	48	49	F	-	S	-	LDACM	57	40	8	-	N	S	-	-	-	-	NSVT	NS VT	LV (subepicardial and intramyocardial)	-	n/a	n		1°		
51118	II:2	Arg81Alafs*15	48	49	F		CP	-	LDACM	52	45	10	-	N	S	-	+	Inf, V4-V6, DI, aVL	-	FVE, NSVT	n/a	LV (subepicardial and intramyocardial)	-	n/a	n				
51118	I:2	Arg81Alafs*15		72	F		n	-	Healthy	48	60	10	-	N	S	-	-	-	-	n/a	n/a	n/a	-	n/a	n				

Grey shaded files indicate probands. Fam= family number. Ind= individual identification according to position in the pedigree. (o)= obligate carrier of the mutation. Age Dx= age at diagnosis. Age LFU= age at last follow-up. M= male; F= female. FHSD= family history of sudden death. Clinical press= signs or symptoms at clinical presentation (D= dyspnea; S= syncope; P= palpitations; AF= atrial fibrillation; NSVT= non-sustained ventricular tachycardia SVT= sustained ventricular tachycardia; FVE= frequent ventricular ectopies; SD= sudden death; CP= chest pain). SM= presence of clinical signs of skeletal myopathy. Pheno= phenotype (DCM= dilated cardiomyopathy; LDAC= left-dominant arrhythmogenic cardiomyopathy; RCM= restrictive cardiomyopathy; affected?= individual possibly affected but not fulfilling diagnosis of a specific cardiomyopathy). LVDD= left ventricular diastole diameter. LVEF= left ventricular ejection fraction (mild= mild depression). MLVWT= maximal left ventricular wall

thickness. RV affect= right ventricular affection (akinesia, dyskinesia, aneurysm, dilatation, systolic dysfunction). CK= plasma levels of creatine-kinase (N= normal value; mild= mild elevation). Rhythm= cardiac rhythm (S= sinus rhythm; AF= atrial fibrillation; PM= pace-maker). CCD= cardiac conduction defects (1°AVB= first-degree AV block; LBBB= left bundle branch block; RBBB= right bundle branch block; LAFB= left anterior fascicular block). Low volt= low QRS voltage amplitude on limb leads. Neg Tw= ECG leads with abnormal negative T waves (inf= DII, DIII, aVF). Vent arrhyt= evidence of ventricular arrhythmias (SVT= sustained ventricular tachycardia; NSVT= non-sustained ventricular tachycardia; FVE= frequent ventricular ectopics). EPS= result of electrical endocavitory stimulation. LGE on MRI= presence and localization of late gadolinium enhancement on cardiac magnetic resonance images. LVNC= signs of myocardial non-compaction of the left ventricular wall (not necessarily fulfilling diagnosis of left ventricular non-compaction cardiomyopathy). Pathology= findings in the pathological evaluation of cardiac necropsy/explanted heart/endomyocardial biopsy. Events= cardiovascular events (SD= sudden death; HTx= heart transplant; aICDs= appropriate ICD shock. ICD= implantable cardiac defibrillator indication (1°= primary prevention; 2°= secondary prevention; ind= indicated but not implanted. + = positive finding. - = negative finding. n/a= not available data. LV= left ventricle. RV= right ventricle. VF= ventricular fibrillation. SAECG= signal average ECG. CRT-D= cardiac resynchronization therapy pacemaker with defibrillation therapy. CABG= coronary artery by-pass graft.

Supplemental Table 5: Logarithm (base ten) of odds (LOD) scores showing cosegregation of truncating mutations in FLNC with the cardiac phenotype in individual families and combined.

Family ID	Mutation	LOD-score (penetrance 99%)
51118	Arg81Alafs*15	0.1758
26958	Tyr83*	0
48924	p.Leu194Profs*52	0.0786
48868	Gly201Valfs*36	n/a
32406	Gln572*	0.095
48028	Lys737Serfs*11	0.0783
29544	Pro963Argfs*26	0.5977
47263	Phe1135Alafs*62	0.0787
41721	c.3791-1G>A	0.3268
27103	c.3791-1G>C	0
48102	c.3791-1G>C	0.2984
49537	c.3965-2A>T	0.3942
49818	c.3965-2A>T	n/a
27348	Asn1369Lysfs*36	0.6364
29876	c.4127+1delG	1.6253
33319	c.4127+1delG	0.9117
48956	c.4580+1G>T	n/a
31277	c.4927+1 delG	n/a
33675	Gly1800*	0.2981
36203	Gly1800*	0.1753
33541	c.5539+1G>C	0.8491
37302	Gly2070Ser	0
25767	Ser2077Argfs*50	0.0789
48888	Pro2081Leufs*2	0.0781
36107	Arg2326*	1.3955
37296	Arg2326*	n/a
31035	c.7251+1G>A	1.3671
37286	Asp2703Thrfs*69	0
Total		9.539

LOD score for each family calculated by means of Superlink-Online SNP tool with the following settings: disease mutant gene frequency= 0.001, dominant mode of inheritance, penetrance= 99%, $\theta=0$. Individuals ≤ 40 years without clear clinical affection were consider “unknown phenotype”. n/a= not available family information.


Supplemental Appendix references

1. Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, et al. Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. *Circ Cardiovasc Genet* 2014;7:751–9.
2. Deo RC, Musso G, Tasan M, et al. Prioritizing causal disease genes using unbiased genomic features. *Genome Biol* 2014;15:3274.
3. Begay RL, Tharp CA, Martin A, et al. FLNC Gene Splice Mutations Cause Dilated Cardiomyopathy. *J Am Coll Cardiol Basic Trans Science* 2016. DOI: 10.1016/j.jacbts.2016.05.004.

Supplemental Figure 1: Pedigrees of families with truncating mutations in *FLNC*.


Fam. 51118

Arg81Alafs*15




Fam. 26958

Tyr83*




Fam. 48924

Leu194Profs*52




Fam. 48868

Gly201Valfs*36




Fam. 32406

Gln572*




Fam. 48028

Lys737Serfs*11




Fam. 29544

Pro963Argfs*26




Fam. 47263


Phe1135Alafs*62




Fam. 41721
c.3791-1G>A




Fam. 27103
c.3791-1G>C




Fam. 48102
c.3791-1G>C




Fam. 49818
c.3965-2A>T




Fam. 49537
c.3965-2A>T




Fam. 27348
Asn1369Lysfs*36




Fam. 33319
c.4127+1delG




Fam. 29876
c.4127+1delG




Fam. 33675
Gly1800*




Fam. 36203
Gly1800*




Fam. 33541
c.5539+1G>C




Fam. 37302
Gly2070Ser




Fam. 25767
Ser2077Argfs*50




Fam. 48888
Pro2081Leufs*2




Fam. 37296
Arg2326*




Fam. 36107
Arg2326*



Fam. 31035
c.7251+1G>A




Fam. 37286
Asp2703Thrfs*69




Supplemental Figure 1: Circles, females. Squares, males. Arrows indicate the proband. Clinical status defined by cardiac evaluations or clinical records: black, affected; N, unaffected; vertical bar, possibly affected; slash, deceased; ?, unknown. Genotypes are indicated: +, FLNC mutation present; 0, obligate carrier; -, FLNC mutation absent. Ages below some individuals indicate the age of sudden death (SD), diagnosis of the phenotype (DCM, dilated cardiomyopathy), or last clinical follow-up in healthy carriers. yo= years old. HTx= heart transplant. PP= palmo-plantar keratoderma. SVT= sustained ventricular tachycardia. HFD= heart failure death. PM= pacemaker.

Supplemental Figure 2: Typical ECG findings in affected carriers of FLNC truncating mutations.




Supplemental Figure 2: ECG from carrier III:2 of family 31035 (Panel A). ECG from carrier II:1 of family 37296 (proband) (Panel B). ECG from carrier III:1 (proband) of family 36203 (Panel C). ECG from carrier II:6 of family 36107 (Panel D).

Supplemental Figure 3: Palmo-plantar keratoderma in carrier II:6 from family 29876.



Supplemental Figure 4: Appropriate defibrillator shock in a patient with a FLNC truncating mutation.



Supplemental Figure 4: Proband III:3 of family 29876. Presented with syncope due to sustained ventricular tachycardia while playing soccer. A cardiac defibrillator was implanted as secondary prevention. Died during a ventricular arrhythmic storm a few days later. Picture shows 10/12 failed appropriate defibrillator shock.